Autres langues BridgeBio Pharma, Inc.

Actions

BBIO

US10806X1028

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
24,33 ^USD	-2,80 %		-2,48 %	-39,73 %

07/04	BridgeBio Pharma, Inc. présente des preuves d'imagerie par résonance magnétique cardiaque (CMR) compatibles avec une amélioration clinique	CI
21/03	BRIDGEBIO PHARMA, INC. : JPMorgan Chase toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BridgeBio Pharma : BBIO – BBO-8520 – 2024 AACR – Rapid and Complete Blockade of Effector Binding Results	23/04
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	10/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy	08/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	07/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	20/03
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing	14/03
BridgeBio Pharma Prices $250 Million Stock Offering	06/03
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	06/03
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	05/03
BridgeBio Pharma Commences $250 Million Share Offering	04/03
BridgeBio Pharma Announces Proposed Public Offering of Common Stock	04/03
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – Development of PROMIS Tool	01/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – FORTIFY Phase 3 Trial Design	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BridgeBio Pharma, Inc.

Actions

BBIO

US10806X1028

Autres langues

Filtres